HTFL
resolvedHeartflow, Inc.
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
HeartFlow is the category-defining pure play in AI-driven, noninvasive coronary artery disease diagnosis. Its FFRct Analysis — which uses deep learning to convert a standard coronary CT angiogram into a functional measurement of blockages without an invasive catheterization — is effectively a quasi-monopoly asset: it is FDA-cleared, Medicare-reimbursed, and embedded in U.S. and European chest-pain guidelines. That positions it in one of healthcare's largest and most underpenetrated markets, since coronary artery disease is the world's leading cause of death and only a low-single-digit percentage of eligible CCTA scans currently carry an FFRct add-on. A +26% gap after earnings signals the market is reclassifying HTFL from a speculative, recently-IPO'd story stock into an established med-tech franchise with durable pricing power and a visible path to profitability. The core rerating argument is operating leverage colliding with reimbursement tailwinds. Revenue growth has been running in the mid-to-high 20s percent with 80%+ gross margins, and the latest print showed losses narrowing toward adjusted EBITDA breakeven — the classic inflection point where each incremental test drops through at very high incremental margin. Simultaneously, CMS improved payment economics for coronary CTA and FFRct, which raises the incentive for hospitals and imaging centers to adopt. The commercial launch of Plaque Analysis alongside RoadMap converts HeartFlow from a single-product company into a multi-product platform that can multiply revenue per scan, while OEM distribution partnerships (notably Siemens Healthineers) extend reach without proportional sales-force spending. There is also a mechanical reason the gap could hold: when a company crosses from cash burn to near self-funding, its shareholder base shifts from venture-style holders to institutional growth investors, and the valuation framework migrates from burn-rate math to growth-adjusted revenue and forward earnings multiples. With Bain Capital still holding a large post-IPO stake and a relatively small float, buyable shares are scarce, which amplifies upside moves on positive catalysts. The key items the Street will now underwrite are sustained 25%+ test volume growth, gross margin holding above 80%, the first cleanly positive adjusted EBITDA quarter, and continued constructive reimbursement commentary out of CMS.
Analyzed by rerate-v2+glm-5.2 · Aug 14, 2026
Catalysts
- Raised full-year 2025 revenue guidance with accelerating FFRct test volume growth in the mid-to-high 20% range
- Imminent crossing of adjusted EBITDA breakeven with 80%+ gross margins, marking the transition to self-funding growth
- Commercial ramp of Plaque Analysis (FDA-cleared) and RoadMap, roughly expanding revenue potential per CCTA scan from a single add-on to a multi-product platform
- Improved CMS reimbursement for coronary CTA + FFRct in the hospital outpatient and physician fee schedules, boosting site-level adoption economics
- OEM distribution partnerships (Siemens Healthineers and others) that lower customer acquisition costs and embed HeartFlow in installed scanner workflows
- International expansion — Japan reimbursement and European guideline traction — opening new addressable volumes
- Post-IPO sell-side initiations and potential index inclusion, with a small float and concentrated insider ownership amplifying flows
Risks
- Reimbursement dependence: a large share of revenue runs through Medicare/CMS rates, and adverse fee schedule or audit decisions would directly hit the model
- Competition: invasive FFR (Abbott), FFRangio (CathWorks), and emerging AI-CT plaque/FFR entrants from large imaging OEMs could erode share or pricing
- GAAP profitability timeline remains uncertain; ongoing losses mean continued reliance on the balance sheet and potential equity raises or dilution
- Ownership concentration: Bain Capital's large stake and post-IPO lock-up expirations create overhang and low-float volatility in both directions
- Valuation: after a 26% gap, the stock trades at a premium price-to-sales multiple that leaves little room for growth deceleration below ~20%
- Long-term clinical risk: GLP-1 penetration could meaningfully reduce cardiac testing volumes over time if metabolic health improves at population scale
- Execution risk in hospital sales cycles — CCTA scanner capacity, ordering cardiologist behavior, and capital budgets can slow adoption
Technical Setup
Forward Returns
Outcomes calculated Aug 21, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| Day 1 | $41.94 | $43.28 | $41.01 | 4.10M |
| Day 2 | $45.23 | $45.33 | $40.67 | 4.17M |
| Day 3 | $45.53 | $47.22 | $44.53 | 2.94M |
| Day 4 | $46.80 | $47.95 | $45.60 | 1.99M |
| 📍 Day 5 | $49.75 | $50.48 | $46.75 | 2.45M |
Signal Breakdown
Gap held — only 0% erased, price maintained gains
Moderate volume decline (40%)
Higher highs with peak close on day 5 — continued buying interest
Minimal drawdown (-3.7%) — price held firm
No fundamental data to evaluate beat quality
Analysis updated Aug 21, 2026